Juan de Vicente

Prof. Juan de Vicente

University of Granada, Granada, Andalusia, Spain
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2011 in Soft Matter
Verified
Journal Article
Closed access
PDF file
Juan de VicenteJuan de Vicente
Juan de Vicente
DKDaniel J. Klingenberg
Daniel J. Klingenberg
RHRoque Hidalgo-Alvarez
Roque Hidalgo-Alvarez
Magnetorheological (MR) materials are a kind of smart materials whose mechanical properties can be altered in a controlled fashion by an external magnetic field. They traditionally include fluids, elastomers and foams. In this review paper we revisit the most outstanding advances on the rheological performance of MR fluids. Special emphasis is paid to the understanding of their yielding, flow and viscoelastic behaviour under shearing flows.

1 April 2020 in Acta Biomaterialia
Verified
Journal Article
Open access
CACristina Antich
Cristina Antich
Juan de VicenteJuan de Vicente
Juan de Vicente
Gema JiménezGema Jiménez
Gema Jiménez
CCCarlos Chocarro
Carlos Chocarro
ECEsmeralda Carrillo
Esmeralda Carrillo
Juan Antonio MarchalJuan Antonio Marchal
Juan Antonio Marchal
Bioprinting is a promising tool to fabricate well-organized cell-laden constructs for repair and regeneration of articular cartilage. The selection of a suitable bioink, in terms of composition and mechanical properties, is crucial for the development of viable cartilage substitutes. In this study, we focused on the use of one of the main cartilage components, hyaluronic acid (HA), to design and formulate a new bioink for cartilage tissue 3D bioprinting. Major characteristics required for this application such as printability, biocompatibility, and biodegradability were analyzed. To produce cartilage constructs with optimal mechanical properties, HA-based bioink was co-printed with polylactic acid (PLA). HA-based bioink was found to improve cell functionality by an increase in the expression of chondrogenic gene markers and specific matrix deposition and, therefore, tissue formation. These results indicate that it is a promising bioink candidate for cartilage tissue engineering based in 3D bioprinting. STATEMENT OF SIGNIFICANCE: The recent appearance of 3D printing technology has enabled great advances in the treatment of osteochondral disorders by fabrication of cartilage tissue constructs that restore and/or regenerate damaged tissue. In this attempt, the selection of a suitable biomaterial, in terms of composition and mechanical properties, is crucial. In this study, we describe for first time the development of a bioink based on the main component of cartilage, HA, with suitable biological and mechanical properties, without involving toxic procedure, and its application in cartilage tissue bioprinting. Hybrid constructs prepared by co-printing this bioink and thermoplastic polymer PLA provided an optimal niche for chondrocyte growth and maintenance as well as mechanical properties necessary to support load forces exerted in native tissue. We highlight the translation potential of this HA-based bioink in the clinical arena.

8 June 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
DJDanna Jennings
Danna Jennings
SHSarah Huntwork-Rodriguez
Sarah Huntwork-Rodriguez
AHAnastasia G. Henry
Anastasia G. Henry
JSJennifer C. Sasaki
Jennifer C. Sasaki
RMRené Meisner
René Meisner
MTMatthew Troyer
Matthew Troyer
Mutations in leucine-rich repeat kinase 2 ( LRRK2 ) are the most common genetic risk factors for Parkinson’s disease (PD). Increased LRRK2 kinase activity is thought to impair lysosomal function and may contribute to the pathogenesis of PD. Thus, inhibition of LRRK2 is a potential disease-modifying therapeutic strategy for PD. DNL201 is an investigational, first-in-class, CNS-penetrant, selective, ATP-competitive, small-molecule LRRK2 kinase inhibitor. In preclinical models, DNL201 inhibited LRRK2 kinase activity as evidenced by reduced phosphorylation of both LRRK2 at serine-935 (pS935) and Rab10 at threonine-73 (pT73), a direct substrate of LRRK2. Inhibition of LRRK2 by DNL201 demonstrated improved lysosomal function in cellular models of disease, including primary mouse astrocytes and fibroblasts from patients with Gaucher disease. Chronic administration of DNL201 to cynomolgus macaques at pharmacologically relevant doses was not associated with adverse findings. In phase 1 and phase 1b clinical trials in 122 healthy volunteers and in 28 patients with PD, respectively, DNL201 at single and multiple doses inhibited LRRK2 and was well tolerated at doses demonstrating LRRK2 pathway engagement and alteration of downstream lysosomal biomarkers. Robust cerebrospinal fluid penetration of DNL201 was observed in both healthy volunteers and patients with PD. These data support the hypothesis that LRRK2 inhibition has the potential to correct lysosomal dysfunction in patients with PD at doses that are generally safe and well tolerated, warranting further clinical development of LRRK2 inhibitors as a therapeutic modality for PD.

1 December 2005 in Tribology Letters
Verified
Journal Article
Closed access
PDF file
Juan de VicenteJuan de Vicente
Juan de Vicente
JSJ.R. Stokes
J.R. Stokes
HSH.A. Spikes
H.A. Spikes

1 June 2006 in Food Hydrocolloids
Verified
Journal Article
Closed access
Juan de VicenteJuan de Vicente
Juan de Vicente
JSJ.R. Stokes
J.R. Stokes
HSH.A. Spikes
H.A. Spikes

4 November 2020 in Soft Matter
Verified
Journal Article
Open access
JMJose R. Morillas
Jose R. Morillas
Juan de VicenteJuan de Vicente
Juan de Vicente
Overview of magnetorheological materials, major characteristics, kinematics and modes of operation.